Supporting Information for

Original article

DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer

Manni Wang[†], Siyuan Chen[†], Yuquan Wei, Xiawei Wei[*]

Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610000, China

Received 22 April 2021; received in revised form 21 June 2021; accepted 9 July 2021

*Corresponding author.

E-mail address: xiaweiwei@scu.edu.cn (Xiawei Wei).

[†]These authors made equal contributions to this work.

Running title: DNA-PK inhibition by M3814 enhances chemosensitivity in NSCLC



B

IC50 (nM)	A549				H460				H1703			
	PTX	M+PTX	Etop	M+ Etop	PTX	M+PTX	Etop	M+ Etop	PTX	M+PTX	Etop	M+ Etop
24h	645.5	6.19	41477	592	1403	2.88	11842	684.2	1800	2.16	23762	602.9
48h	386.1	0.24	39754	73.37	15.15	0.27	711.2	10.01	0.98	0.14	5279	252.2
72h	11.14	0.15	450	4.51	0.85	0.004	305	3.32	0.42	0.01	2011	6.957

Figure S1 Synergistic inhibition of M3814 and chemotherapy on NSCLC cell viability and colony formation *in vitro*. (A) Cell viability curves of NSCLC cell lines A549 and H460 treated with paclitaxel/etoposide (0–100 mmol/L) with or without M3814 (5 μmol/L) for 24, 48 and 72 h. Data are presented as mean ± SD (n = 3). (B) The IC_{50} of chemotherapy on NSCLC cell lines calculated according to CCK-8 assay results.



Figure S2 Toxicity evaluation. (A) and (B) Body weight curves and mean body weight of mice at the end of treatment. Data are presented as mean ± SD (n = 7; ns, P > 0.05). (C) Blood biochemical analysis of mice with indicated treatments. Data are presented as mean ± SD (n = 3; *P < 0.05), with no significant differences in biochemical indexes shown between groups according to ANOVA multiple comparison tests.